SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Cytokinetics

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential securities law violations at Cytokinetics, Inc. following a significant stock drop after the FDA extended the review period for its heart drug aficamten due to the company's failure to submit a Risk Evaluation and Mitigation Strategy (REMS) with its New Drug Application (NDA) [3][2]. Company Summary - Cytokinetics, Inc. (NASDAQ: CYTK) experienced a stock decline of $5.57, or 12.9%, closing at $37.35 per share on May 2, 2025, after the FDA's announcement regarding the extended review period for aficamten [3]. - The company admitted to initially filing its NDA without a REMS, despite prior discussions with the FDA about safety and risk mitigation [3]. Legal Investigation - Faruqi & Faruqi, LLP, a national securities law firm, has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [2]. - The firm is encouraging investors who suffered losses in Cytokinetics to contact them to discuss their legal options [1][4].